Armata Pharmaceuticals, Inc. (ARMP) Dividend History

Armata Pharmaceuticals, Inc. is a biotechnology company focused on developing bacteriophage-based therapies to treat bacterial infections. The company leverages its proprietary platform to create targeted phage products aimed at addressing unmet medical needs, particularly antibiotic-resistant infections. Founded with a focus on innovative approaches to combat bacterial pathogens, Armata aims to offer effective alternatives to traditional antibiotics.

Dividend History

Armata Pharmaceuticals, Inc. currently does not pay dividends

Company News

8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - Pipeline Innovations Expected to Add $1.8 Billion in Bronchiectasis Market Sales

The report forecasts the bronchiectasis treatment market to reach $3.7 billion by 2033, driven by emerging pipeline agents expected to contribute an additional $1.8 billion in sales.

GlobeNewswire Inc.

Featured Companies: INSM REGN
Phage Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight

The phage therapy market is experiencing significant growth due to the increasing prevalence of antibiotic-resistant infections and the growing interest in alternative treatments. Advances in biotechnology and ongoing research are driving innovation in phage-based therapeutics, offering a promising solution to combat multidrug-resistant pathogens.

GlobeNewswire Inc.

Featured Companies: PHGE
Bronchiectasis Market to Show Positive Growth at a CAGR of 13.7% by 2034 | DelveInsight

The bronchiectasis market is expected to grow at a CAGR of 13.7% from 2024 to 2034, driven by the launch of new treatments like Brensocatib and CMS I-neb, advancements in diagnostics, and the increasing incidence of the disease.

GlobeNewswire Inc.

Featured Companies: INSM
Groundbreaking Insights Unveiled in Non-Cystic Fibrosis Bronchiectasis Pipeline Report

The report discusses emerging therapies for non-cystic fibrosis bronchiectasis, a chronic lung condition, including Brensocatib and HSK31858, which are in advanced clinical trials and show promise in reducing inflammation and improving patient outcomes.

GlobeNewswire Inc.

Featured Companies: INSM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates

Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -12.50% and 0.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research

Featured Companies: YMAB

Dividend data last updated 06/07/2025 14:26:41 UTC